Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.03.01.22271254: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization 12] For this COVID-SAFER: Nirmatrelvir-ritonavir study, we analyzed data from the 5698 patient cluster randomized MedSafer trial, which ran from August 2017 to January 2020.[ Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The software applies a ruleset for the identification of PIMs which includes common recommendations from expert groups.[ PIMssuggested: (PiMS, RRID:SCR_011816)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecogniz…SciScore for 10.1101/2022.03.01.22271254: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization 12] For this COVID-SAFER: Nirmatrelvir-ritonavir study, we analyzed data from the 5698 patient cluster randomized MedSafer trial, which ran from August 2017 to January 2020.[ Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources The software applies a ruleset for the identification of PIMs which includes common recommendations from expert groups.[ PIMssuggested: (PiMS, RRID:SCR_011816)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of this study are the theoretical nature of the “drug exposure” to only one treatment for COVID-19; however, with millions of courses of nirmitrelvir-ritonavir purchased worldwide, it is expected to be a common exposure. This analysis could also be replicated for other promising potential outpatient treatments, such as fluvoxamine, which also has several DDIs.[29] We also focused this paper on PIMs; however, the majority of interacting medications were not PIMs. We have provided medication management guidance for many of these medications elsewhere.[12] It is also important to recognize that stopping PIMs requires clinical judgment when formulating a deprescribing plan. The strength of this study is the large sample size of representative community dwelling older adults with polypharmacy who are at high risk of severe COVID-19 complications; arguably, one of the populations most likely to benefit from treatment with nirmatrevir-ritonavir.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04960202 Active, not recruiting EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With P… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
